

Color	Population	Event	% Total
	Vista Positive [Hek Positive control]	12713	37.03
	Vista Positive [HEK B7H5 OE Positive control]	8625	26.10

Figure 1A



Figure 1B



Figure 1C



Color	Population	Antibody	%Total
	HEK293	V4	2.25
	HEK293 VISTA O/E	V4	61.54

Figure 1D



	Color	Population	Antibody	Live Cells	MFI
1		HEK293 VISTA O/E	Unstained	9604	0.12
2		HEK293 VISTA O/E	Isotype	10088	0.06
3		HEK293-WT	9M2C12	8922	0.1
4		HEK293-WT	V4	9301	0.11
5		HEK293 VISTA O/E	VSTB1 12	10800	8.47
6		HEK293 VISTA O/E	9M2C12	9463	8.45
7		HEK293 VISTA O/E	V4	9398	14.91

Figure 2

V4 Conc. (nM)	Response	KD (M)	KD Error	kon(1/Ms)	kon Error	kdis(1/s)	RMax	RMax Error	kobs(1/s)	Req	Req/ Rmax(%)	Full X^2	Full R^2
1000	1.1009	**<1.0E-12**	1.73E-09	**4.54E+04**	1.20E+03	**<1.0E-07**	1.0869	0.0077	4.54E-02	1.0869	100	0.1009	**0.9961**
500	0.881	**<1.0E-12**	1.73E-09	**4.54E+04**	1.20E+03	**<1.0E-07**	0.9508	0.0114	2.27E-02	0.9508	100	0.1009	**0.9961**
250	0.699	**<1.0E-12**	1.73E-09	**4.54E+04**	1.20E+03	**<1.0E-07**	0.975	0.0185	1.13E-02	0.975	100	0.1009	**0.9961**
125	0.4105	**<1.0E-12**	1.73E-09	**4.54E+04**	1.20E+03	**<1.0E-07**	0.872	0.0228	5.67E-03	0.872	100	0.1009	**0.9961**
62.5	0.2962	**<1.0E-12**	1.73E-09	**4.54E+04**	1.20E+03	**<1.0E-07**	1.094	0.0343	2.83E-03	1.094	100	0.1009	**0.9961**
31.3	0.0618	**<1.0E-12**	1.73E-09	**4.54E+04**	1.20E+03	**<1.0E-07**	0.4238	0.0342	1.42E-03	0.4238	100	0.1009	**0.9961**

Figure 3A

V4 Conc. (nM)	Response	KD (M)	KD Error	kon(1/Ms)	kon Error	kdis(1/s)	RMax	RMax Error	kobs(1/s)	Req	Req/ Rmax(%)	Full X^2	Full R^2
1433	0.688	**<1.0E-12**	2.10E-09	**4.02E+04**	1.12E+03	**<1.0E-07**	0.6759	0.0047	5.76E-02	0.6759	100	0.0332	**0.9927**
716.5	0.6052	**<1.0E-12**	2.10E-09	**4.02E+04**	1.12E+03	**<1.0E-07**	0.6264	0.0066	2.88E-02	0.6264	100	0.0332	**0.9927**
358.3	0.4609	**<1.0E-12**	2.10E-09	**4.02E+04**	1.12E+03	**<1.0E-07**	0.5714	0.0101	1.44E-02	0.5714	100	0.0332	**0.9927**
179.1	0.3216	**<1.0E-12**	2.10E-09	**4.02E+04**	1.12E+03	**<1.0E-07**	0.5837	0.0147	7.20E-03	0.5837	100	0.0332	**0.9927**
1433	0.688	**<1.0E-12**	2.10E-09	**4.02E+04**	1.12E+03	**<1.0E-07**	0.6759	0.0047	5.76E-02	0.6759	100	0.0332	**0.9927**

Figure 3B

V4 Conc. (nM)	Response	KD (M)	KD Error	kon(1/Ms)	kon Error	kdis(1/s)	kdis Error	RMax	RMax Error	kobs(1/s)	Req	Req/ Rmax(%)	Full X^2	Full R^2
666.5	0.4104	1.13E-07	5.65E-09	3.95E+04	1.58E+03	4.45E-03	1.34E-04	0.4719	0.0083	3.08E-02	0.4036	85.5	0.0099	0.9948
333.3	0.2261	1.13E-07	5.65E-09	3.95E+04	1.58E+03	4.45E-03	1.34E-04	0.3459	0.0097	1.76E-02	0.2584	74.7	0.0099	0.9948
166.6	0.1064	1.13E-07	5.65E-09	3.95E+04	1.58E+03	4.45E-03	1.34E-04	0.2573	0.0101	1.10E-02	0.1534	59.6	0.0099	0.9948
83.3	0.0514	1.13E-07	5.65E-09	3.95E+04	1.58E+03	4.45E-03	1.34E-04	0.207	0.0116	7.74E-03	0.0879	42.5	0.0099	0.9948
41.7	0.0275	1.13E-07	5.65E-09	3.95E+04	1.58E+03	4.45E-03	1.34E-04	0.1952	0.0172	6.10E-03	0.0527	27	0.0099	0.9948

Figure 3C



	Human VISTA	Mouse VISTA	Cyno VISTA	PDL1	HER3
EC_{50} (M)	2.56E-10	5.93E-09	2.82E-10	N/A	N/A

Figure 4A



Figure 4B



Figure 5



Figure 6



Figure 7A



Figure 7B



Figure 8A



Figure 8B



Figure 9



Figure 10


SDS-PAGE
M1
1
2
200 kDa---
116 kDa---
97 kDa---
66 kDa---
44 kDa---
29 kDa---
20 kDa---
14 kDa---
6 kDa---
Western Blot
M2
P
1
2
120 kDa---
80 kDa---
60 kDa---
50 kDa---
42 kDa---
32 kDa---
18 kDa---

Figure 11



Arms	Dose	Cmax (ug/ml)	Tmax (hr)	AUC0-336 (ug*h/ml)	AUC0-Infinity (ug*h/ml)	T1/2	CL	Vd
						(hr)	(ml/h)	(mL/kg)
V4P	25mg/kg	143.05	6.00	31382.88	47118.67	211.79	0.01	3.84

Figure 12



Figure 13



Figure 14


CELL ABUNDANCE ESTIMATED FROM BULK RNA-SEQ
Anti-Vista
Anti-PDL1 + Anti-Vista
Anti-PDL1
PBS
450
500
550
600
650
Post-treatment MDSC
In contrast to treatment with anti-PDL1 alone, anti-VISTA monotherapy or in combination reduces MDSC abundance
Anti-Vista
Anti-PDL1 + Anti-Vista
Anti-PDL1
PBS
0.35
0.40
0.45
0.50
Post-treatment CD8/T-reg ratios

Figure 15



Figure 16



Figure 17



Figure 18



Figure 19A



Figure 19B



Figure 20



Figure 21



Figure 22


4T1 Tumor Volume
Tumor Volume (mm3)
1800
1200
600
0
Dosing:
0
5
10
15
20
Days Post Implantation
PBS
Isotype
13D5-1 (300 ug)
13D5-1 (600 ug)
70% TGI

Figure 23


2M1-D2
4M2-C9
5M1-A11
9M2-C12
2M1-B12
1M2-D2
4M2-A8
4M2-B4
4M2-D9
4M2-D5
Color Population
HEK293
HEK293 VISTA O/E
100%
75%
50%
25%
1e1
1e2
1e3
FITC-A B1-A

Figure 24

mFcγRIV

k_{on} = ND K_D = ND k_{dis} = ND



Figure 25A

mFcγRIII

k_{on} = 2.7e^5 M^{-1} s^{-1} K_D = 455 nM k_{dis} = 12.5e^{-2} s^{-1}



Figure 25B

mFcγRIIb

k_{on} = 0.90e^5 M^{-1} s^{-1} K_D = 1300 nM k_{dis} = 11.7e^{-2} s^{-1}



Figure 25C

mFcRn

k_{on} = 1.7e^5 M^{-1} s^{-1} K_D = 93.9 nM k_{dis} = 1.6e^{-2} s^{-1}



Figure 25D

mFcγRIV

$k_{on} = 0.92e^5\ M^{-1}\ s^{-1}$ $K_D = 372\ nM$ $k_{dis} = 3.4e^{-2}\ s^{-1}$



Figure 26A

mFcγRIII

$k_{on} = 0.67e^5\ M^{-1}\ s^{-1}$ $K_D = 977\ nM$ $k_{dis} = 6.6e^{-2}\ s^{-1}$



Figure 26B

mFcγRIIb

$k_{on} = 0.55e^{5}\ M^{-1}\ s^{-1}$ $K_D = 2190\ nM$ $k_{dis} = 12.0e^{-2}\ s^{-1}$



Figure 26C

mFcRn

$k_{on} = 2.2e^{5}\ M^{-1}\ s^{-1}$ $K_D = 49.6\ nM$ $k_{dis} = 1.1e^{-2}\ s^{-1}$



Figure 26D



Figure 27A



Figure 27B



Figure 27C



Figure 27D

mFcγRIV

k_{on} = ND K_D = ND k_{dis} = 34.8e^{-2} s^{-1}



Figure 28A

mFcγRIII

k_{on} = ND K_D = ND k_{dis} = ND



Figure 28B

mFcγRIIb

k_{on} = ND K_D = ND k_{dis} = ND



Figure 28C

mFcRn

k_{on} = 1.8e^5 M^{-1} s^{-1} K_D = 42.5 nM k_{dis} = 0.75e^{-2} s^{-1}



Figure 28D

Calculated k_{on} (M^{-1} s^{-1})

Receptor	4M2-C12 mIgG2a k_{on} ($M^{-1}s^{-1}$)		4M2-C12 mIgG1 k_{on} ($M^{-1}s^{-1}$)	4M2-C12 mIgG2a LALA_PG k_{on} ($M^{-1}s^{-1}$)	4M2-C12 mIgG2a NQ k_{on} ($M^{-1}s^{-1}$)
	1	2			
mFcRn	$1.9e^5$	$2.2e^5$	$1.7e^5$	$2.7e^5$	$1.8e^5$
mFcgRIV	$0.96e^5$	$0.92e^5$	ND	ND	ND
mFcgRIII	$0.55e^5$	$0.67e^5$	$2.7e^5$	ND	ND
mFcgRIIb	$0.51e^5$	$0.55e^5$	$0.90e^5$	ND	ND

ND = Not Determined due to low binding affinity

Figure 29A

Calculated k_{dis} (s^{-1})

Receptor	4M2-C12 mIgG2a k_{dis} (s^{-1})		4M2-C12 mIgG1 k_{dis} (s^{-1})	4M2-C12 mIgG2a LALA_PG k_{dis} (s^{-1})	4M2-C12 mIgG2a NQ k_{dis} (s^{-1})
	1	2			
mFcRn	$0.59e^{-2}$	$1.1e^{-2}$	$1.6e^{-2}$	$0.97e^{-2}$	$0.75e^{-2}$
mFcgRIV	$2.5e^{-2}$	$3.4e^{-2}$	ND	ND	$34.8e^{-2}$
mFcgRIII	$4.4e^{-2}$	$6.6e^{-2}$	$12.5e^{-2}$	ND	ND
mFcgRIIb	$4.5e^{-2}$	$12.0e^{-2}$	$11.7e^{-2}$	ND	ND

ND = Not Determined due to low binding affinity

Figure 29B

Calculated K_D (nM)

Receptor	Gene	Function	Binding affinity	Reported K_D (nM)		4M2-C12 mIgG2a K_D (nM)		4M2-C12 mIgG1 K_D (nM)	4M2-C12 mIgG2a LALA_PG K_D (nM)	4M2-C12 mIgG2a NQ K_D (nM)
						1	2			
mFcRn	FCGRT	Recycling (Increased affinity → Increased half life)	Medium	mIgG1: 1157 mIgG2a: 490 mIgG2b: 545 mIgG3: 140	hIgG1: 72 hIgG2: 63 hIgG3: 230 hIgG4: 116	31.5	49.5	93.9	35.8	42.5
mFcgRIV	CD16-2	Cell activation	High	mIgG1: ND mIgG2a: 34.5 mIgG2b: 59 mIgG3: ND	hIgG1: 280 hIgG2: 0 hIgG3: 170 hIgG4: 26000	258	372	ND	ND	ND
mFcgRIII	CD16	Cell activation	Low	mIgG1: 3200 mIgG2a: 1460 mIgG2b: 1555 mIgG3: ND	hIgG1: 9300 hIgG2: 9700 hIgG3: 1300 hIgG4: 21000	794	977	455	ND	ND
mFcgRIIb	CD32	Cell inhibition	Low	mIgG1: 301 mIgG2a: 2390 mIgG2b: 448 mIgG3: ND	hIgG1: 1100 hIgG2: 7900 hIgG3: 700 hIgG4: 11000	876	2190	1300	ND	ND

ND = K_D Not Determined due to low binding affinity

Figure 29C



Figure 30A



Figure 30B


Tumor Volume (mm3)
2000
1500
1000
500
0
10
12
14
16
18
20
22
24
Days Post-implantation
Vehicle Control
4M2-C12 mIgG2a-LALAPG
Antibody Injection

Figure 30C


V4 Epitope Binning with VSTB112 and IGENICA 175A (In-Tandem)
hVista + V4 + IGN175A
hVista + V4 + VSTB112
hVista + V4 + V4
hVista + VSTB112 + V4
hVista + IGN175A + V4
hVista + VSTB112 + VSTB112
PBS + VSTB112 + IGN175A
PBS + VSTB112 + V4
Epitope Binning Cycle Data
Competing antibody
Saturating antibody
X-Axis: Time (s)
Y-Axis: Shift (nm)

Figure 31A


hVista + IGN175A + V4-C1
hVista + V4-C1 + IGN175A
hVista + V4-C1 + V4-C1
hVista + V4-C1 + VSTB112
hVista + IGN175A + IGN175A
hVista + VSTB112 + IGN175A
hVista + VSTB112 + V4-C1
PBS + V4-C1 + IGN175A
Epitope Binning Cycle Data
Competing antibody
Saturating antibody
Y-Axis: Shift (nm)
X-Axis: Time (s)

Figure 31B



Figure 32



Figure 33A


100
50
0
CD4+CFSE-low %
Control Ig
VISTA Ig
VISTA Ig + V4 (20 ug/ml)
VISTA Ig + V4 (50 ug/ml)
VISTA Ig + VSTB112 (20 ug/ml)

Figure 33B


100
50
0
CD8+CFSE-low %
Control Ig
VISTA Ig
VISTA Ig + V4 (20 ug/ml)
VISTA Ig + V4 (50 ug/ml)
VISTA Ig + VSTB112 (20 ug/ml)

Figure 33C


100
50
0
CD8+CFSE-low%
Control Ig
VISTA Ig
VISTA Ig + V4 (20 ug/ml)
VISTA Ig + V4 (50 ug/ml)
VISTA Ig + VSTB112 (20 ug/ml)

Figure 33D



Figure 34A



Figure 34B



Figure 35



Figure 36A



Figure 36B



Figure 37



Figure 38A



Figure 38B



Figure 38C



Figure 38D



Figure 38E



Figure 39



Figure 40A



Figure 40B



Figure 41



Figure 42



Figure 43


30
20
10
0
Mouse Weight (g)
PBS
V4
Anti-PDL1
V4 & Anti-PDL1
5
10
15
20
25
Antibody Injection
Days Post-implantation

Figure 44



Figure 45A



Figure 45B



Figure 45C

Antibody	mouse VISTA			human VISTA		
	K_D (nM)	K_{on} (M^{-1} s^{-1})	K_{dis} (s^{-1})	K_D (nM)	K_{on} (M^{-1} s^{-1})	K_{dis} (s^{-1})
V4_C1	60.7	2.43E+05	14.7E-03	<0.001	3.43E+05	<1.0E-07
V4_C9	3.81	3.11E+05	1.18E-03	<0.001	3.33E+05	<1.0E-07
V4_C24	<0.001	4.01E+05	<1.0E-07	<0.001	3.84E+05	<1.0E-07
V4_C26	<0.001	4.03E+05	<1.0E-07	<0.001	4.04E+05	<1.0E-07
V4_C27	<0.001	4.26E+05	<1.0E-07	<0.001	4.65E+05	<1.0E-07
V4_C28	0.17	4.75E+05	0.082E-03	<0.001	5.07E+05	<1.0E-07
V4_C30	0.005	5.05E+05	0.0028E-03	<0.001	5.93E+05	<1.0E-07
V4_C31	<0.001	5.70E+05	<1.0E-07	<0.001	6.23E+05	<1.0E-07

Figure 45D



Figure 46A

Antibody	mouse VISTA		
	K_D (nM)	K_{on} ($M^{-1} s^{-1}$)	K_{dis} (s^{-1})
V4_C1	66.7	3.30E+05	22.0E-03
V4_C9	4.26	1.57E+05	0.67E-03
VSTB112	NS	NS	NS
V4_C24	<0.001	4.62E+05	<1.0E-07
V4_C26	0.183	4.13E+05	0.076E-03
V4_C27	0.137	3.98E+05	0.055E-03
V4_C28	0.489	5.20E+05	0.25E-03
V4_C30	<0.001	5.33E+05	<1.0E-07
V4_C31	<0.001	3.44E+05	<1.0E-07

Figure 46B



Figure 47A



Figure 47B

Antibody	human VISTA			mouse VISTA		
	K_D (nM)	K_{on} (M^{-1} s^{-1})	K_{dis} (s^{-1})	K_D (nM)	K_{on} (M^{-1} s^{-1})	K_{dis} (s^{-1})
V4_C1	<0.001	3.91E+05	<1.0E-07	58.5	2.77E+05	16.2E-03
V4_C9	0.125	4.50E+05	0.056E-03	2.88	3.61E+05	1.04E-03
VSTB112	<0.001	1.79E+05	<1.0E-07	NA	NA	NA
V4_C24	<0.001	3.73E+05	<1.0E-07	0.202	3.78E+05	0.076E-03
V4_C26	0.241	4.07E+05	0.098E-03	0.530	3.82E+05	0.20E-03
V4_C27	0.119	5.11E+05	0.061E-03	0.395	3.92E+05	0.16E-03

Figure 47C



Figure 48A

	human VISTA			mouse VISTA		
Antibody	K_D (nM)	k_{on} (M^{-1} s^{-1})	k_{dis} (s^{-1})	K_D (nM)	k_{on} (M^{-1} s^{-1})	k_{dis} (s^{-1})
V4	<0.001	$128e^3$	$<0.01e^{-5}$	108	$60.9e^3$	$656e^{-5}$
VSTB112	<0.001	$210e^3$	$<0.01e^{-5}$	NS	NS	NS

Figure 48B



Figure 49A



Figure 49B

	V4pr	V4_C1	V4_C9	V4_C24	V4_C26	V4_C27	V4_C28	V4_C30	V4_C31	ATZ	VSTB112	Isotype
hVISTA	0.036	0.0024	0.031	0.010	0.0034	<0.0007	0.0015	<0.0007	0.0032	102	0.042	152
mVISTA	0.43	3.1	0.11	0.017	0.0089	0.0023	0.0045	0.0013	0.0030	97	>200	77

Figure 49C


hVISTA
1.0
0.8
0.6
0.4
0.2
0.0
-0.2
A450
10-16 10-15 10-14 10-13 10-12 10-11 10-10 10-9 10-8 10-7 10-6
Conc. (M)
V4C1
V4C9
V4C24
V4C26
V4C27
V4C28
V4C30
V4C31
VST112
Hu Isotype

Figure 50A



Figure 50B

	V4_C1	V4_C9	V4_C24	V4_C26	V4_C27	V4_C28	V4_C30	V4_C31	VSTB112	Isotype
hVISTA	0.042	0.030	0.032	0.038	0.037	0.053	0.088	0.020	0.054	> 200
mVISTA	1.60	0.044	0.042	0.058	0.047	0.064	0.123	0.028	> 200	> 200

Figure 50C



Figure 51A



Figure 51B

	V4C24	V4C26	V4C27	V4C1	V4C9	VSTB112	Hu Isotype
hVISTA	0.073	0.064	0.047	0.065	0.107	0.072	98.5
mVISTA	0.116	0.086	0.073	2.44	0.180	>200	>200

Figure 51C



Figure 52A



Figure 52B



Figure 52C



Figure 52D



Figure 52E



Figure 52F



Figure 52G



Figure 52H



Figure 52I

	Tm		
	Fc	Fab	
Antibody	Tm1 (℃)	Tm2 (℃)	Shoulder
V4p	67.5		Shoulder at 63
V4_C1	70.5		
V4_C9	75.1		Shoulder at 72C
V4_C24	72.3		
V4_C26	72.9		
V4_C27	70.3	75.6	
V4_C28	70.5	76.3	
V4_C30	70.2	77.5	
V4_C31	74.5		Shoulder at 71.5C
VSTB112	69.9	82.3	

Figure 52J

Antibody	% identity (human)		Potentially Immunogenic peptides	
	HC	LC	HC	LC
V4	69.7	63.2	2	3
V4_C1	86.9	85.3	6	3
V4_C9	86.9	86.3	4	3
V4_C24	85.9	85.3	2	3
V4_C26	85.9	85.3	2	2
V4_C27	85.9	85.3	2	3
V4_C28	85.9	85.3	2	3
V4_C30	85.9	84.2	2	3
V4_C31	85.9	83.2	2	2

Figure 53



Figure 54



Figure 55



Figure 56A



Figure 56B



Figure 56C



Figure 56D



Figure 56E



Figure 56F



Figure 56G



Figure 57A



Figure 57B



Figure 57C



Figure 57D



Figure 57E



Figure 57F



Figure 57G



Figure 57H

EC_{50} (M)	human VISTA	mouse VISTA	Rat VISTA	Cyno VISTA
V4	3.19E-11	3.87E-10	1.25E-09	4.72E-11
V4C24	2.68E-11	3.04E-11	2.01E-10	3.85E-11
V4C26	2.41E-11	3.25E-11	1.60E-10	3.56E-11
V4C27	2.95E-11	3.74E-11	1.96E-10	3.24E-11
V4C28	3.46E-11	3.65E-11	2.17E-10	3.67E-11
V4C30	3.18E-11	3.26E-11	2.06E-10	2.72E-11
V4C31	4.08E-11	4.00E-11	2.24E-10	3.21E-11
Isotype	> 3.3e-008	> 3.3e-008	> 3.3e-008	> 3.3e-008

Figure 57I



Figure 58A


HEK293-6E O/E Human VISTA
1
2
3
4
5
6
7
8
9
10
1 0 1 1e1 1e2 1e3
FITC-A B1-A

Figure 58B


HEK293-6E O/E Mouse VISTA
1
2
3
4
5
6
7
8
9
10
1 0 1 1e1 1e2 1e3
FITC-A B1-A

Figure 58C



Figure 59A



Figure 59B



Figure 60A



Figure 60B



Figure 60C



Figure 60D



Figure 61A



Figure 61B



Figure 61C



Figure 62



Arms	Dose	Cmax (ug/ml)	Tmax (hr)	AUC0-336 (ug*h/ml)	AUC0-Infinity (ug*h/ml)	T1/2 (hr)	CL (ml/h)	Vd (mL/kg)
V4P hIgG1	10 mg/kg	1264.925	6.000	163820.857	535540.716	494.683	0.005	3.631
V4P hIgG4	10 mg/kg	756.632	6.000	157719.024	325944.397	324.881	0.008	3.726

Figure 63A



Arms	Dose	Cmax (ug/ml)	Tmax (hr)	AUC0-336 (ug*h/ml)	AUC0-Infinity (ug*h/ml)	T1/2 (hr)	CL (ml/h)	Vd (mL/kg)
V4P hIgG1	25 mg/kg	917.691	6.000	168137.409	624496.133	637.687	0.010	9.622
V4P hIgG4	25 mg/kg	1532.665	6.000	343433.514	790153.226	380.006	0.008	4.467

Figure 63B



Arms	Dose	Cmax (ug/ml)	Tmax (hr)	AUC0-336 (ug*h/ml)	AUC0-Infinity (ug*h/ml)	T1/2 (hr)	CL (ml/h)	Vd (mL/kg)
V4P hIgG1	100 mg/kg	5158.909	6.000	951642.588	1836917.880	340.466	0.014	6.425
V4P hIgG4	100 mg/kg	5286.726	6.000	876440.678	1078777.776	144.581	0.023	4.644

Figure 63C



Arms	Dose	Cmax (ug/ml)	Tmax (hr)	AUC0-336 (ug*h/ml)	AUC0-Infinity (ug*h/ml)	T1/2 (hr)	CL (ml/h)	Vd (mL/kg)
V4P hIgG1	250mg/kg	11293.381	6.000	1806847.108	4415613.763	448.196	0.014	9.049
V4P hIgG4	250mg/kg	1532.665	6.000	343433.514	790153.226	380.006	0.008	4.467

Figure 63D

Treatment Arm	Dose	Red Blood Cell						
		RBC Count (10^9/L)	Hemoglobin (g/dl)	Hematocrit (%)	Anemia Parameters			Platelet count (10^9/L)
					MCV (fml)	MCH (pg)	MCHC (g/dl)	
Vehicle	0	10.73	16.3	45.67	43	15.2	35.7	774
V4P	50 mg/kg	11.02	17.2	47.64	43	15.6	36	720

Figure 64A

Treatment Arm	Dose	White Blood Cell			
		WBC Count (10^9/ L)	Lymphocyte Count (10^9/ L)	Monocyte Count (10^9/ L)	Neutrophil Count (10^9/ L)
Vehicle	0	5.57	3.4	0.05	1.7
V4P	50 mg/kg	5.98	4.22	0.05	1.71

Figure 64B

Treatment Arm	Dose	Biochemistry			
		Liver (U/L)		Kidney (mg/dL)	
		ALT	ALP	CREA	BUN
Vehicle	0	29	102	17	0.2
V4P	50 mg/kg	23	50	19	0.2

Figure 64C

Treatment Arm	Time (hrs)	Red Blood Cell						
		RBC Count (10^9/L)	Hemoglobin (g/dl)	Hematocrit (%)	Anemia Parameters			Platelet count (10^9/L)
					MCV (fml)	MCH (pg)	MCHC (g/dl)	
Vehicle	0	7.94	14.97	45.50	57.33	18.87	32.87	223.3
	6	8.58	16.15	48.57	56.50	18.90	17.80	886.5
	24	8.25	15.70	46.55	56.33	19.03	33.73	427.0
	96	7.97	13.37	45.39	56.67	16.80	29.50	229.0
	168	8.27	15.87	46.96	57.00	19.20	33.80	244.7
V4 IgG1	0	7.65	14.30	43.82	57.33	18.60	41.73	172.3
	6	8.03	14.77	45.04	56.33	18.50	32.90	99.00
	24	8.14	14.73	45.84	56.33	18.17	32.23	305.7
	96	7.97	13.93	45.02	56.33	17.50	30.97	269.3
	168	8.15	15.50	45.53	55.67	19.03	34.03	151.1
V4 IgG4	0	7.94	14.23	46.23	58.00	17.83	30.63	247.0
	6	10.51	20.40	61.26	58.33	19.40	33.30	427.3
	24	8.04	14.90	45.31	56.00	18.50	32.83	293.3
	96	6.77	12.23	38.43	57.00	18.07	31.70	183.7
	168	7.69	13.73	43.65	57.00	17.97	31.53	303.0

Figure 65A

Treatment Arm	Time (hrs)	White Blood Cell			
		WBC Count (10^9/ L)	Lymphocyte Count (10^9/ L)	Monocyte Count (10^9/ L)	Neutrophil Count (10^9/ L)
Vehicle	0	14.86	12.53	0.40	1.93
	6	10.88	8.63	0.21	2.03
	24	9.85	8.15	0.20	1.50
	96	11.68	8.94	0.59	2.15
	168	15.82	12.28	1.22	2.32
V4 IgG1	0	9.02	7.52	0.55	0.94
	6	8.79	5.84	0.35	2.60
	24	10.38	8.66	0.16	1.57
	96	10.89	8.91	0.35	1.63
	168	19.90	17.23	0.82	1.73
V4 IgG4	0	8.42	7.38	0.08	0.96
	6	18.20	10.76	0.62	6.82
	24	7.44	5.73	0.48	1.23
	96	7.32	5.56	0.15	1.61
	168	10.05	8.44	0.34	1.28

Figure 65B

Treatment Arm	Time (hrs)	Biochemistry									
		Liver (U/L)		Kidney (mg/dL)		Pancreas		Electrolytes			
		ALT	ALP	CREA	BUN	GLU (mg/dL)	AMY (U/L)	NA (meq/L)	K (meq/L)	P (mg/dL)	CA (mg/dL)
Vehicle	0	52.33	246.0	0.33	21.33	173.7	549.3	137.3	7.90	8.47	11.33
	6	28.67	210.7	0.37	10.33	195.7	517.7	134.0	6.00	8.20	10.87
	24	36.67	258.0	0.40	13.33	182.0	564.3	137.7	6.73	7.77	11.27
	96	32.33	218.3	0.10	12.67	178.3	532.0	134.0	5.50	8.07	10.93
	168	40.33	283.0	0.27	13.00	190.0	623.3	135.7	6.37	7.30	11.13
V4 IgG1	0	31.00	259.0	0.27	11.67	175.3	619.0	137.3	7.23	8.33	11.33
	6	35.67	261.7	0.33	12.00	140.3	590.0	139.3	8.43	9.97	11.63
	24	33.67	257.3	0.20	12.33	154.0	639.0	136.3	7.57	8.10	11.30
	96	35.67	235.7	0.23	11.50	181.7	648.0	135.7	6.67	8.33	11.20
	168	38.67	269.7	0.23	13.33	179.7	657.0	136.7	7.00	8.20	11.33
V4 IgG4	0	38.33	277.0	0.30	11.67	171.3	622.3	135.3	7.23	8.43	11.23
	6	57.00	217.0	0.20	10.00	138.7	469.0	144.3	44.03	8.20	11.15
	24	34.67	275.0	0.33	12.33	158.3	633.0	134.7	6.70	8.07	11.10
	96	36.00	196.3	0.23	11.67	172.0	585.7	138.0	8.90	9.23	11.53
	168	36.00	229.3	0.30	14.00	179.0	644.7	136.3	6.90	7.67	11.23

Figure 65C